Results preview: Year 2018

Thursday, 28 February 2019.

Reig Jofre closes 2018 with a turnover 180.5 M€ and EBITDA of 16.4 M€.

  • The sales growth of 7% allowed the turnover to reach € 180.5M. Within the good performance of Reig Jofre business units highlighted 35% growth in the nutritional supplements line of Forté Pharma in France
  • Forté Pharma, Reig Jofre's nutritional supplements line, closed an excellent year thanks to new launches in the weight, energy and sleep control ranges, mainly
  • The lines of antibiotics and freeze-dried injectable products from the pharmaceutical technologies area closed important international agreements in Indonesia, among others
  • EBITDA showed a positive evolution of 4% compared to 2017 and stood at € 16.4M
  • Personnel expenses increased by 6% as a result of the reinforcement of international commercial structures, especially in France result of the strong growth rate in sales and additions linked to the increase of productive capacity in Spain
  • Other operating expenses grew by 11% compared to 2017, in line with previous quarters, largely due to the increase in marketing and advertising expenses related to the Nutritional Supplements area; the increase in R&D expenditure and, to a lesser extent, the impact of the new installed capacity at the Toledo plant
  • The effort in R&D continued with an expenditure over € 9.5M in 2018. As a result of this effort, product development projects were activated for an amount of € 4.8M

Download the full document (PDF)

This site uses only technical third party cookies to provide better service, when browsing this website you agree to its use. See ourlegal advice. Agree

Our website is protected by DMC Firewall!